The Effects of Remdesivir and Dexamethasone on Renal Sirtuin-1 Expression and Renal Function in Male Rats
Abstract Remdesivir (REM) and dexamethasone (DEX) both have been used to treat coronavirus disease 2019 (COVID-19). The present study aimed to evaluate the effects of REM and DEX on kidney structure and function with particular focus on the probable renal sirtuin-1 (SIRT1) expression alteration in rats. Twenty-four male Wistar rats were divided into four groups, as follows: group A (control) received normal saline (5 mL/kg/day for 10 days); group B (REM) received REM (17 mg/kg/day on the first day, and 8.5 mg/kg/day on the 2nd–10th days); group C (REM + DEX) received both REM (17 mg/kg/day on the first day, and 8.5 mg/kg/day on the 2nd–10th days) and DEX (7 mg/kg/day, for 10 days); group D (DEX) received DEX (7 mg/kg/day for 10 days). Renal SIRT1 expression and kidney structure and function-related factors were evaluated by standard methods. The mean levels of urea in the REM + DEX group (60.83 ± 6.77, mg/dL) were significantly higher than in the control (48.33 ± 3.01, mg/dL; p = 0.002) and DEX (51.22 ± 4.99, mg/dL; p = 0.018) groups. The mean levels of creatinine in the REM (0.48 ± 0.08, mg/dL) and REM + DEX (0.50 ± 0.04, mg/dL) groups were higher than in the control group (48.33 ± 3.0 mg/dL) significantly (p = 0.022 and p = 0.010, respectively). The renal SIRT1 expression was significantly (p = 0.018) lower in the REM + DEX group (0.36 ± 0.35) than in the control group (1.34 ± 0.48). Tubulointerstitial damage (TID) scores in REM + DEX-treated rats (2.60 ± 0.24) were significantly higher than in the control (0.17 ± 0.17, p = 0.001) and DEX (0.50 ± 0.29, p = 0.005) groups. The administration of DEX and REM might lead to kidney injury associated with SIRT1 downregulation..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:196 |
---|---|
Enthalten in: |
Applied biochemistry and biotechnology - 196(2023), 2 vom: 11. Mai, Seite 632-642 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Danaiyan, Sepideh [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
---|
Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
---|
doi: |
10.1007/s12010-023-04529-3 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR05475237X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR05475237X | ||
003 | DE-627 | ||
005 | 20240214064651.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240214s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12010-023-04529-3 |2 doi | |
035 | |a (DE-627)SPR05475237X | ||
035 | |a (SPR)s12010-023-04529-3-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Danaiyan, Sepideh |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Effects of Remdesivir and Dexamethasone on Renal Sirtuin-1 Expression and Renal Function in Male Rats |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
520 | |a Abstract Remdesivir (REM) and dexamethasone (DEX) both have been used to treat coronavirus disease 2019 (COVID-19). The present study aimed to evaluate the effects of REM and DEX on kidney structure and function with particular focus on the probable renal sirtuin-1 (SIRT1) expression alteration in rats. Twenty-four male Wistar rats were divided into four groups, as follows: group A (control) received normal saline (5 mL/kg/day for 10 days); group B (REM) received REM (17 mg/kg/day on the first day, and 8.5 mg/kg/day on the 2nd–10th days); group C (REM + DEX) received both REM (17 mg/kg/day on the first day, and 8.5 mg/kg/day on the 2nd–10th days) and DEX (7 mg/kg/day, for 10 days); group D (DEX) received DEX (7 mg/kg/day for 10 days). Renal SIRT1 expression and kidney structure and function-related factors were evaluated by standard methods. The mean levels of urea in the REM + DEX group (60.83 ± 6.77, mg/dL) were significantly higher than in the control (48.33 ± 3.01, mg/dL; p = 0.002) and DEX (51.22 ± 4.99, mg/dL; p = 0.018) groups. The mean levels of creatinine in the REM (0.48 ± 0.08, mg/dL) and REM + DEX (0.50 ± 0.04, mg/dL) groups were higher than in the control group (48.33 ± 3.0 mg/dL) significantly (p = 0.022 and p = 0.010, respectively). The renal SIRT1 expression was significantly (p = 0.018) lower in the REM + DEX group (0.36 ± 0.35) than in the control group (1.34 ± 0.48). Tubulointerstitial damage (TID) scores in REM + DEX-treated rats (2.60 ± 0.24) were significantly higher than in the control (0.17 ± 0.17, p = 0.001) and DEX (0.50 ± 0.29, p = 0.005) groups. The administration of DEX and REM might lead to kidney injury associated with SIRT1 downregulation. | ||
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Dexamethasone |7 (dpeaa)DE-He213 | |
650 | 4 | |a Nephrotoxicity |7 (dpeaa)DE-He213 | |
650 | 4 | |a Remdesivir |7 (dpeaa)DE-He213 | |
650 | 4 | |a Sirtuin-1 |7 (dpeaa)DE-He213 | |
700 | 1 | |a Abbasi, Mehran Mesgari |4 aut | |
700 | 1 | |a Raeisi, Sina |4 aut | |
700 | 1 | |a Argani, Hassan |4 aut | |
700 | 1 | |a Ghorbanihaghjo, Amir |4 aut | |
700 | 1 | |a Shanehbandi, Dariush |4 aut | |
700 | 1 | |a Roshangar, Leila |4 aut | |
700 | 1 | |a Poursistany, Haniyeh |4 aut | |
700 | 1 | |a Abedi, Sara |4 aut | |
700 | 1 | |a Mohammadian, Jamal |4 aut | |
700 | 1 | |a Bahremani, Mona |4 aut | |
700 | 1 | |a Rashtchizadeh, Nadereh |0 (orcid)0000-0003-2878-3847 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Applied biochemistry and biotechnology |d Berlin : Springer, 1976 |g 196(2023), 2 vom: 11. Mai, Seite 632-642 |w (DE-627)SPR02354368X |w (DE-600)2072711-2 |x 1559-0291 |7 nnns |
773 | 1 | 8 | |g volume:196 |g year:2023 |g number:2 |g day:11 |g month:05 |g pages:632-642 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12010-023-04529-3 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 196 |j 2023 |e 2 |b 11 |c 05 |h 632-642 |